

1/21

Figure 1a

<----- signal sequence ----->
M A L P V T A L L L P L A L L L H A A R
atggccttaccagtgaccgccttgctcctgccgctggccttgctgctccacgccgcccagg

-> <----- Immunoglobulin like domain ----->
P S Q F R V S P L D R T W N L G E T V E
ccgagccagttccgggtgtcgccgctggatcggaacctgggagacagtgagg

----->
L K C Q V L L S N P T S G C S W L F Q P
ctgaagtgccaggtgctgctgtccaacccgacgtcgggctgctcgtggctcttccagccg

----->
R G A A A S P T F L L Y L S Q N K P K A
cgcgggcgccgcccagtgccaccttctcctatacctctcccaaacaagcccaaggcg

----->
A E G L D T Q R F S G K R L G D T F V L
gccgaggggctggacaccagcggttctcgggcaagaggttgggggacaccttcgtcctc

----->
T L S D F R R E N E G Y Y F C S A L S N
accctgagcgacttccgcccagagaacgagggctactatcttctgctcggccctgagcaac

-----> <----->
S I M Y F S H F V P V F L P A K P T T T
tccatcatgtacttcagccacttcgtgccggtcttctcctgccagcgaagcccaccacgacg

--- membrane proximal domain --->
P A P R P P T P A P T I A S Q P L S L R
ccagcgccgcgaccaccaacacggcgcccaccatcgctcgcagcccctgtccctgcgc

----->
P E A C R P A A G G A V H T R G L D F A
ccagaggcgtgccggccagcgggcgggggcgagtgacacgagggggctggacttcgcc

-> <----- Transmembrane domain ----->
C D I Y I W A P L A G T C G V L L L S L
tgtgatctacatctggggcgcccttggccgggacttggtggggctcttctcctgtcactg

-----> <----- Cytoplasmic domain ----->
V I T L Y C N H R N R R R V C K C P R P
gttatcaccctttactgcaaccacaggaaccgaagacgtgtttgcaaatgtccccggcct

2/21

----->
V V K S G D K P S L S A R Y V *
gtggtcaaatacgggagacaagcccagcctttcggcgagatacgtctaa

Figure 1b

<----- Immunoglobulin like domain ----->
M S Q F R V S P L D R T W N L G E T V E
atgAGtCAaTTtCGtGTaTCaCCGCTGGATCGGACCTGGAACCTGGGCGAGACAGTGGAG

L K C Q V L L S N P T S G C S W L F Q P
CTGAAGTGCCAGGTGCTGCTGTCCAACCCGACGTCGGGCTGCTCGTGGCTCTTCCAGCCG

R G A A A S P T F L L Y L S Q N K P K A
CGCGGCGCCGCGCCAGTCCCACCTTCCTCCTATACCTCTCCCAAACAAGCCCAAGGCG

A E G L D T Q R F S G K R L G D T F V L
GCCGAGGGGCTGGACACCCAGCGTTCTCGGGCAAGAGGTTGGGGGACACCTTCGTCCTC


T L S D F R R E N E G Y Y F C S A L S N
ACCCTGAGCGACTTCCGCGGAGAGAACGAGGGCTACTATTTCTGCTCGGCCCTGAGCAAC
-----> <Membrane p.d.
S I M Y F S H F V P V F L P A K P T T T
TCCATCATGTACTTCAGCCACTTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGACG

P *
CCATAG

[SEQ ID NO: 23]


3/21

Fig.2



4/21

Fig.3.



5 / 21

Fig.4A





Fig.4B



6 / 21

Fig.5A





Fig.5B



7/21

Fig.6.






Fig.7.




8 / 21

Fig.8



9/21


Fig.9



10/21

Fig.10


Effect of CD8 and CD8 mutants on CTL lysis



11/21



Fig.11

Effect of CD8 on CTL lysis




12 / 21

Fig.12



13/21

Fig.13



14/21

Fig.14






Fig.15



15/21

Fig.16.




16 / 21

Figure 17

Biotinylated sCD8 α /OX68 immobilised

Concentration of HLA-A2/Pol :



17/21

Figure 18

```
<----- signal/leader peptide----->
M A S P L T R F L S L N L L L L G E S I
ATGGCCTCACCGTTGACCCGCTTTCTGTCGCTGAACCTGCTGCTGCTGGGTGAGTCGATT

-----> <---- immunoglobulin domain ----->
I L G S G E A K P Q A P E L R I F P K K
ATCCTGGGGAGTGAGAGAAGCTAAGCCACAGGCACCCGAACCTCCGAATCTTTCCAAAGAAA

----- . -----
M D A E L G Q K V D L V C E V L G S V S
ATGGACGCCGAACCTTGGTCAGAAGGTGGACCTGGTATGTGAAGTGTTGGGGTCCGTTTCG

----- # -----
Q G C S W L F Q N S S S K L P Q P T F V
CAAGGATGCTCTTGGCTCTTCCAGAACTCCAGCTCCAAACTCCCCAGCCCACCTTCGTT

-----
V Y M A S S H N K I T W D E K L N S S K
GTCTATATGGCTTCATCCCACAACAAGATAACGTGGGACGAGAAGCTGAATTCGTCGAAA

-----
L F S A M R D T N N K Y V L T L N K F S
CTGTTTTCTGCCATGAGGGACACGAATAATAAGTACGTTCTCACCCTGAACAAGTTCAGC

----- . -----
K E N E G Y Y F C S V I S N S V M Y F S
AAGGAAAACGAAGGCTACTATTTCTGCTCAGTCATCAGCAACTCGGTGATGTACTTCAGT

-----> <----- stalk region ----->
S V V P V L Q K V N S T T T K P V L R T
TCTGTCGTGCCAGTCCTTCAGAAAGTGAACCTCTACTACTACCAAGCCAGTGCTGCGAACT

-----
P S P V H P T G T S Q P Q R P E D C R P
CCCTCACCTGTGCACCCTACCGGGACATCTCAGCCCCAGAGACCAGAAGATTGTGGCCCC

-----> <----- transmembrane domain ----->
R G S V K G T G L D F A C D I Y I W A P
CGTGGCTCAGTGAAGGGGACCGGATTGGACTTCGCCTGTGATATTTACATCTGGGCACCC

----->
L A G I C V A L L L S L I I T L I C Y H
TTGGCCGGAATCTGCGTGGCCCTTCTGCTGTCCTTGATCATCACTCTCATCTGCTACCAC
```

18/21

<----- cytoplasmic domain ----->
R S R K R V C K C P R P L V R Q E G K P
AGGAGCCGAAAGCGTGTGTTGCAAATGTCCCAGGCCGCTAGTCAGACAGGAAGGCAAGCCC
----->
R P S E K I V *
AGACCTTCAGAGAAAATTGTGTAA

Figure 19

Nde I


M K P Q A P E L R I F P K K M D A E L
catatgAAaCCACaAGCACcTGAACtACGAATCTTTCCAAAGAAAATGGACGCCGAACtT
G Q K V D L V C E V L G S V S Q G C S W
GGTCAGAAGGTGGACCTGGTATGTGAAGTGTGTTGGGGTCCGTTTCGCAAGGATGCTCTTGG
L F Q N S S S K L P Q P T F V V Y M A S
CTCTTCCAGAACTCCAGCTCCAAACTCCCCAGCCACCTTCGTTGTCTATATGGCTTCA
S H N K I T W D E K L N S S K L F S A M
TCCCACAACAAGATAACGTGGGACGAGAAGCTGAATTCGTCGAAACTGTTTTCTGCCATG
R D T N N K Y V L T L N K F S K E N E G
AGGGACACGAATAATAAGTACGTTCTCACCTGAACAAGTTCAGCAAGGAAAACGAAGGC
Y Y F C S V I S N S V M Y F S S V V P V
TACTATTTCTGCTCAGTCATCAGCAACTCGGTGATGTACTTCAGTTCTGTCTGCGCCAGTC


HindIII



L Q K V N S T T T K P *
CTTCAGAAAGTGAACtCTACTACTACCAAGCCAtaagctt

[SEQ ID NO: 24]

Fig.20





21/21
Figure 22Human CD8 inhibition of CTL priming in vivo 2×10^6 pfu Vac. G2 + PBS 2×10^6 pfu Vac. G2 + 4mgCD8


Day 6




Cells washed from spleen



Day 6

Spleen cells plated
with $1 \mu\text{M}$ peptide
LCMV gp 33-41

Day 10

Added Cr^{51} labelled
target cells presenting
LCMV gp 33-41
peptide

Measure killing